Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials
Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy. Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH. Methods: Combined data from 6 phas...
Gespeichert in:
| Veröffentlicht in: | HIV research & clinical practice 2021-07, Vol.22 (2), p.46-54 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 2 |
| container_start_page | 46 |
| container_title | HIV research & clinical practice |
| container_volume | 22 |
| creator | Spinelli, Frank Prakash, Manyu Slater, Jill van der Kolk, Mike Bassani, Niccolò Grove, Richard Wynne, Brian van Wyk, Jean Clark, Andrew |
| description | Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy.
Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH.
Methods: Combined data from 6 phase III/IIIb trials in treatment-naive (ARIA, FLAMINGO, SINGLE, SPRING-2; N = 2634) and treatment-experienced (DAWNING, SAILING; N = 1339) participants receiving dolutegravir- or non-dolutegravir-based regimens were analyzed by age ( |
| doi_str_mv | 10.1080/25787489.2021.1941672 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_25787489_2021_1941672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4176bce433b2463580ff6ef6d2dfbc94</doaj_id><sourcerecordid>2545989237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-99d920d7d9b119b21e73a013d0c0929c33b1c4a7ac7bfd74caaae62a9da050ca3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEElXpT0DykUsW23HimBOoUIhUiQucrYk9Dq68drCzhT3zx_GypeLEaWae3vvm8JrmJaM7Rkf6mvdylGJUO0452zEl2CD5k-bipLdSSPr0cR_V8-aqlDtKq1UyqrqL5tf7FA4bLhnufW5nKGhJxsXvMRbiI9kywlaPrY3g75FAtP9o-HPF7DGamoLFx4WsaT0E2HyK5U01QzgWLCQ5MpD1W6WTaZqICT56A6GSPITyonnm6sCrh3nZfL358OX6U3v7-eN0_e62NaIftlYpqzi10qqZMTVzhrIDyjpLDVVcma6bmREgwcjZWSkMAODAQVmgPTXQXTbTmWsT3Ok1-z3ko07g9R8h5UVD3rwJqAWTw2xQVCYXQ9eP1LkB3WC5dbNRorJenVlrTt8PWDa998VgCBAxHYrmvejVqHgnq7U_W01OpWR0j68Z1acO9d8O9alD_dBhzb0953x0Ke_hR8rB6g2OIWWXIRpfdPd_xG-JIKWY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545989237</pqid></control><display><type>article</type><title>Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials</title><source>Alma/SFX Local Collection</source><creator>Spinelli, Frank ; Prakash, Manyu ; Slater, Jill ; van der Kolk, Mike ; Bassani, Niccolò ; Grove, Richard ; Wynne, Brian ; van Wyk, Jean ; Clark, Andrew</creator><creatorcontrib>Spinelli, Frank ; Prakash, Manyu ; Slater, Jill ; van der Kolk, Mike ; Bassani, Niccolò ; Grove, Richard ; Wynne, Brian ; van Wyk, Jean ; Clark, Andrew</creatorcontrib><description><![CDATA[Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy.
Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH.
Methods: Combined data from 6 phase III/IIIb trials in treatment-naive (ARIA, FLAMINGO, SINGLE, SPRING-2; N = 2634) and treatment-experienced (DAWNING, SAILING; N = 1339) participants receiving dolutegravir- or non-dolutegravir-based regimens were analyzed by age (<50, ≥50 to <65, and ≥65 years). Baseline data included comorbidities and numbers of concomitant medications. Week 48 efficacy outcomes included virologic response (HIV-1 RNA <50 copies/mL) and CD4+ cell count change from baseline. Safety outcomes included incidence of adverse events (AEs), serious AEs, and AE-related withdrawals.
Results: Use of ≥5 concomitant medications was more frequently reported among treatment-naive and treatment-experienced participants aged ≥50 to <65 (30% [90/296] and 25% [57/227], respectively) and ≥65 years (43% [10/23] and 29% [4/14]) than among those aged <50 years (13% [310/2315] and 11% [118/1098]). Comorbidities were more prevalent in the older age groups. For dolutegravir-based regimens, Week 48 rates of virologic response and change in CD4+ cell count were similar across age groups (treatment naive, 80-87% and 234-251 cells/mm
3
; treatment experienced, 70-100% and 105-156 cells/mm
3
, respectively). There were no major differences in safety outcomes in each age group.
Conclusions: In these analyses of combined phase III/IIIb trial data, efficacy and safety of dolutegravir-based regimens were generally similar across age groups in treatment-naive or treatment-experienced participants. Polypharmacy and comorbidities were more common among OALWH than those aged <50 years.]]></description><identifier>ISSN: 2578-7489</identifier><identifier>EISSN: 2578-7470</identifier><identifier>DOI: 10.1080/25787489.2021.1941672</identifier><language>eng</language><publisher>Taylor & Francis</publisher><subject>antiretroviral therapy ; comorbidities ; integrase strand transfer inhibitor ; older adults living with HIV ; polypharmacy ; virologic suppression</subject><ispartof>HIV research & clinical practice, 2021-07, Vol.22 (2), p.46-54</ispartof><rights>2021 ViiV Healthcare. Published by Informa UK Limited, trading as Taylor & Francis Group. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-99d920d7d9b119b21e73a013d0c0929c33b1c4a7ac7bfd74caaae62a9da050ca3</citedby><cites>FETCH-LOGICAL-c456t-99d920d7d9b119b21e73a013d0c0929c33b1c4a7ac7bfd74caaae62a9da050ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Spinelli, Frank</creatorcontrib><creatorcontrib>Prakash, Manyu</creatorcontrib><creatorcontrib>Slater, Jill</creatorcontrib><creatorcontrib>van der Kolk, Mike</creatorcontrib><creatorcontrib>Bassani, Niccolò</creatorcontrib><creatorcontrib>Grove, Richard</creatorcontrib><creatorcontrib>Wynne, Brian</creatorcontrib><creatorcontrib>van Wyk, Jean</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><title>Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials</title><title>HIV research & clinical practice</title><description><![CDATA[Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy.
Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH.
Methods: Combined data from 6 phase III/IIIb trials in treatment-naive (ARIA, FLAMINGO, SINGLE, SPRING-2; N = 2634) and treatment-experienced (DAWNING, SAILING; N = 1339) participants receiving dolutegravir- or non-dolutegravir-based regimens were analyzed by age (<50, ≥50 to <65, and ≥65 years). Baseline data included comorbidities and numbers of concomitant medications. Week 48 efficacy outcomes included virologic response (HIV-1 RNA <50 copies/mL) and CD4+ cell count change from baseline. Safety outcomes included incidence of adverse events (AEs), serious AEs, and AE-related withdrawals.
Results: Use of ≥5 concomitant medications was more frequently reported among treatment-naive and treatment-experienced participants aged ≥50 to <65 (30% [90/296] and 25% [57/227], respectively) and ≥65 years (43% [10/23] and 29% [4/14]) than among those aged <50 years (13% [310/2315] and 11% [118/1098]). Comorbidities were more prevalent in the older age groups. For dolutegravir-based regimens, Week 48 rates of virologic response and change in CD4+ cell count were similar across age groups (treatment naive, 80-87% and 234-251 cells/mm
3
; treatment experienced, 70-100% and 105-156 cells/mm
3
, respectively). There were no major differences in safety outcomes in each age group.
Conclusions: In these analyses of combined phase III/IIIb trial data, efficacy and safety of dolutegravir-based regimens were generally similar across age groups in treatment-naive or treatment-experienced participants. Polypharmacy and comorbidities were more common among OALWH than those aged <50 years.]]></description><subject>antiretroviral therapy</subject><subject>comorbidities</subject><subject>integrase strand transfer inhibitor</subject><subject>older adults living with HIV</subject><subject>polypharmacy</subject><subject>virologic suppression</subject><issn>2578-7489</issn><issn>2578-7470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUFv1DAQhSMEElXpT0DykUsW23HimBOoUIhUiQucrYk9Dq68drCzhT3zx_GypeLEaWae3vvm8JrmJaM7Rkf6mvdylGJUO0452zEl2CD5k-bipLdSSPr0cR_V8-aqlDtKq1UyqrqL5tf7FA4bLhnufW5nKGhJxsXvMRbiI9kywlaPrY3g75FAtP9o-HPF7DGamoLFx4WsaT0E2HyK5U01QzgWLCQ5MpD1W6WTaZqICT56A6GSPITyonnm6sCrh3nZfL358OX6U3v7-eN0_e62NaIftlYpqzi10qqZMTVzhrIDyjpLDVVcma6bmREgwcjZWSkMAODAQVmgPTXQXTbTmWsT3Ok1-z3ko07g9R8h5UVD3rwJqAWTw2xQVCYXQ9eP1LkB3WC5dbNRorJenVlrTt8PWDa998VgCBAxHYrmvejVqHgnq7U_W01OpWR0j68Z1acO9d8O9alD_dBhzb0953x0Ke_hR8rB6g2OIWWXIRpfdPd_xG-JIKWY</recordid><startdate>20210713</startdate><enddate>20210713</enddate><creator>Spinelli, Frank</creator><creator>Prakash, Manyu</creator><creator>Slater, Jill</creator><creator>van der Kolk, Mike</creator><creator>Bassani, Niccolò</creator><creator>Grove, Richard</creator><creator>Wynne, Brian</creator><creator>van Wyk, Jean</creator><creator>Clark, Andrew</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20210713</creationdate><title>Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials</title><author>Spinelli, Frank ; Prakash, Manyu ; Slater, Jill ; van der Kolk, Mike ; Bassani, Niccolò ; Grove, Richard ; Wynne, Brian ; van Wyk, Jean ; Clark, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-99d920d7d9b119b21e73a013d0c0929c33b1c4a7ac7bfd74caaae62a9da050ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>antiretroviral therapy</topic><topic>comorbidities</topic><topic>integrase strand transfer inhibitor</topic><topic>older adults living with HIV</topic><topic>polypharmacy</topic><topic>virologic suppression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spinelli, Frank</creatorcontrib><creatorcontrib>Prakash, Manyu</creatorcontrib><creatorcontrib>Slater, Jill</creatorcontrib><creatorcontrib>van der Kolk, Mike</creatorcontrib><creatorcontrib>Bassani, Niccolò</creatorcontrib><creatorcontrib>Grove, Richard</creatorcontrib><creatorcontrib>Wynne, Brian</creatorcontrib><creatorcontrib>van Wyk, Jean</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>HIV research & clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spinelli, Frank</au><au>Prakash, Manyu</au><au>Slater, Jill</au><au>van der Kolk, Mike</au><au>Bassani, Niccolò</au><au>Grove, Richard</au><au>Wynne, Brian</au><au>van Wyk, Jean</au><au>Clark, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials</atitle><jtitle>HIV research & clinical practice</jtitle><date>2021-07-13</date><risdate>2021</risdate><volume>22</volume><issue>2</issue><spage>46</spage><epage>54</epage><pages>46-54</pages><issn>2578-7489</issn><eissn>2578-7470</eissn><abstract><![CDATA[Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy.
Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH.
Methods: Combined data from 6 phase III/IIIb trials in treatment-naive (ARIA, FLAMINGO, SINGLE, SPRING-2; N = 2634) and treatment-experienced (DAWNING, SAILING; N = 1339) participants receiving dolutegravir- or non-dolutegravir-based regimens were analyzed by age (<50, ≥50 to <65, and ≥65 years). Baseline data included comorbidities and numbers of concomitant medications. Week 48 efficacy outcomes included virologic response (HIV-1 RNA <50 copies/mL) and CD4+ cell count change from baseline. Safety outcomes included incidence of adverse events (AEs), serious AEs, and AE-related withdrawals.
Results: Use of ≥5 concomitant medications was more frequently reported among treatment-naive and treatment-experienced participants aged ≥50 to <65 (30% [90/296] and 25% [57/227], respectively) and ≥65 years (43% [10/23] and 29% [4/14]) than among those aged <50 years (13% [310/2315] and 11% [118/1098]). Comorbidities were more prevalent in the older age groups. For dolutegravir-based regimens, Week 48 rates of virologic response and change in CD4+ cell count were similar across age groups (treatment naive, 80-87% and 234-251 cells/mm
3
; treatment experienced, 70-100% and 105-156 cells/mm
3
, respectively). There were no major differences in safety outcomes in each age group.
Conclusions: In these analyses of combined phase III/IIIb trial data, efficacy and safety of dolutegravir-based regimens were generally similar across age groups in treatment-naive or treatment-experienced participants. Polypharmacy and comorbidities were more common among OALWH than those aged <50 years.]]></abstract><pub>Taylor & Francis</pub><doi>10.1080/25787489.2021.1941672</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2578-7489 |
| ispartof | HIV research & clinical practice, 2021-07, Vol.22 (2), p.46-54 |
| issn | 2578-7489 2578-7470 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_25787489_2021_1941672 |
| source | Alma/SFX Local Collection |
| subjects | antiretroviral therapy comorbidities integrase strand transfer inhibitor older adults living with HIV polypharmacy virologic suppression |
| title | Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dolutegravir-based%20regimens%20in%20treatment-naive%20and%20treatment-experienced%20aging%20populations:%20analyses%20of%206%20phase%20III%20clinical%20trials&rft.jtitle=HIV%20research%20&%20clinical%20practice&rft.au=Spinelli,%20Frank&rft.date=2021-07-13&rft.volume=22&rft.issue=2&rft.spage=46&rft.epage=54&rft.pages=46-54&rft.issn=2578-7489&rft.eissn=2578-7470&rft_id=info:doi/10.1080/25787489.2021.1941672&rft_dat=%3Cproquest_cross%3E2545989237%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545989237&rft_id=info:pmid/&rft_doaj_id=oai_doaj_org_article_4176bce433b2463580ff6ef6d2dfbc94&rfr_iscdi=true |